In a few years time the next generation CAR-T cell therapies are going to look and behave very differently from the somewhat crude versions we use in the clinic today, making them more akin to the homemade wooden go-carts of our misspent youth.

This is what science and technology is all about improvisation and innovation to create something bigger, better, faster, or even safer than what went before.

It’s a rite of passage just as many Dads and siblings went through numerous iterations of building go-carts, so too will we see a similar evolution in this cell therapy niche, although obviously more rapidly and on a much grander scale than those humble efforts to improve the speed or manoeuvreability we were all ardently obsessed with. Brakes, I have to admit didn’t even come into the equation until much later when a near-miss got us all grounded, but oh the fun we all had in the process!

If we want to improve the selectivity and killing capacity of the new CARs in both liquid and solid tumours, what practical aspects ought to be considered and how is synthetic biology going to get us there?

In our expert interview, we sought to learn how an expert in the field saw how things might be changing and where they could be shifting…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by